Alzheimer s & Dementia · 2021 · 63 citations · 6 references
MedicineGeriatric MedicineNeurologyDementiaGeriatric CareGeriatricsAlzheimer DiseaseCognitive AssessmentCognitive ImpairmentDementia BiomarkersDementia CareDementia TreatmentAlzheimer’s Disease CareCapacity Assessment In DementiaCapacity Determination In DementiaCognitive Performance TestingConfirmatory Diagnostic TestingHealth System ImplementationInfusion DurationWait Times For Care
INTRODUCTION: A 2017 study had analyzed the preparedness of the U.S. health care system to deliver a disease-modifying Alzheimer's treatment and predicted substantial wait times. We update the prediction with an improved model and newer data. METHODS: The model tracks patients from initial evaluation, cognitive testing by a dementia specialist, confirmatory biomarker testing, and infusion delivery. All steps after initial evaluation are assumed to be capacity constrained. Model parameters and assumptions about care-seeking behavior were derived from the published literature and expert input. RESULTS: If patients were referred based on a brief cognitive test, wait times for specialist visits would reach around 50 months. If referral also required a positive blood-based biomarker test, wait times would be around 12 months. In both scenarios, wait times for confirmatory biomarker testing and infusion treatment would be limited. DISCUSSION: Better diagnostic tools at initial evaluation may reduce unnecessary delays in access to treatment.
6
Gil D. Rabinovici, Constantine Gatsonis, Charles Apgar et al. · JAMA · 2019 · 667 citations · Full text
Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity
Lampros Kourtis, Oliver B. Regele, Justin M. Wright et al. · npj Digital Medicine · 2019 · 466 citations · Full text
Medicine, Life Sciences, Neurology +18
Soeren Mattke, Sang Kyu Cho, Tobias Bittner et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 2020 · 70 citations · Full text